US · Healthcare · Medical Devices
EPS came in at 2.62 against a street estimate of 2.34 — a beat of 12.0%.
Analysts rate Bio-Rad Laboratories Inc a hold (1 buy, 1 hold, 1 sell out of 3) with an average price target of $328.33.
MIXED Q2 flat YoY, but sequential improvement. Digital PCR strong (+6% instruments >20%). Life Science weak; Clinical Diagnostics returned to growth. Announced $30-35M restructuring with 40-50 bps margin benefit in 2027. FY guidance reaffirmed despite China headwinds. Q2 2026 Americas recovery gradual; China remains challenged by order timing and academic softness; EMEA benefiting from Middle East restock but facing logistics headwinds. Analysts pressed on ddPCR durability post-Stilla anniversary and China trajectory. Management emphasized organic competitive strength and local manufacturing progress. Tariff and Sartorius monetization logistics discussed; no refunds charged to customers yet; tax treatment case-specific. 2026-08-04…
Full summary in the app.
| Fund | Stake |
|---|---|
| Arnhold & S. Bleichroeder Advisers, LLC | 19.49% |
| BlackRock Inc | 6.35% |
| Dimensional Fund Advisors, Inc. | 3.53% |
| Vanguard Capital Management, LLC | 3.09% |
| Ariel Investments, LLC | 3.05% |
| Vanguard Portfolio Management, LLC | 3.05% |
| Earnest Partners LLC | 2.17% |
| State Street Corp | 2.14% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 BIO-RAD LABORATORIES, INC. – FORM 10-Q SUMMARY Period Ended June 30, 2026 --- HEADLINE NUMBERS • Total Assets: $10,252.0 million (down from $10,576 | 2026-08-04 |
| Results announced · Q3 2026 BIO-RAD LABORATORIES Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Q2 2026 net sales: $651.0 million vs. $651.6 million in Q2 2025 (essentially flat | 2026-08-04 |
| Quarterly report · Q1 2026 BIO-RAD LABORATORIES, INC. – Q1 2026 10-Q SUMMARY --- HEADLINE NUMBERS • Net Sales Q1 2026: $592.1 million (vs. $585.4 million in Q1 2025) – growth | 2026-04-30 |
| Results announced · Q2 2026 BIO-RAD LABORATORIES Q1 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Q1 2026 Net Sales: $592.1 million, up 1.1% year-over-year (compared to $585.4 mill | 2026-04-30 |
| Board / officer change · Q2 2026 BIO-RAD LABORATORIES, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Annual stockholder meeting held April 21, 2026 • 335,000 additional shares of commo | 2026-04-24 |
| Proxy statement · Q2 2026 BIO-RAD LABORATORIES, INC. - PROXY STATEMENT SUMMARY WHAT SHAREHOLDERS ARE VOTING ON • Item 1: Election of six directors—Class A Common Stock holder | 2026-03-25 |
| Reg FD disclosure · Q1 2026 BIO-RAD LABORATORIES, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Sartorius AG Investment Update: Bio-Rad disclosed financial data for its investment | 2026-02-19 |
| Annual report FY2025 BIO-RAD LABORATORIES, INC. - 10-K SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Company: Bio-Rad Laboratories, Inc. – multinational life science a | 2026-02-13 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Bio-Rad Laboratories Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.